Leadership

Jan Møller Mikkelsen founded Ascendis Pharma in 2007 and has served as President and Chief Executive Officer, as well as Board member since then. From 2002 to 2006, Mr. Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S (now Veloxis Pharmaceuticals A/S). From 2000 to 2002, Mr. Mikkelsen was President of the Pharmaceutical Division of Maxygen, Inc. Prior to that, Mr. Mikkelsen co-founded ProFound Pharma A/S (a biopharmaceutical company acquired by Maxygen, Inc.), where he served as Co-Chief Executive Officer from 1999 to 2000. From 1988 to 1999, Mr. Mikkelsen held various positions at Novo Nordisk A/S, a global healthcare company, including Vice President of Protein Discovery. In late 2021, Mr. Mikkelsen was named Chairman of the Board of Directors of Hummingbird Bioscience, a clinical-stage biotechnology company focused on cancer and autoimmune disease. He received a Cand. Scient. degree in Biochemistry from the University of Odense, Denmark and pursued his post-doctoral research at Children’s Hospital Oakland in Oakland, California, U.S.

Sherrie Glass was named Chief Business Officer at Ascendis Pharma in September 2024, where her responsibilities include identifying and capitalizing on strategic opportunities and leading Business Development, Global Marketing, Commercial Operations & Analytics, and Health Economic & Outcomes Research (HEOR). Prior to joining Ascendis, Ms. Glass was Senior Vice President of Enterprise Strategy & Operational Excellence at Bristol Myers Squibb from 2021 to 2024, where she oversaw the company’s strategic plan, ran portfolio prioritization for the mid- to late-stage R&D portfolio, drove Therapeutic Area strategy, and was deeply involved in Business Development, licensing, and M&A. Her earlier roles included serving as Vice President, U.S. Managed Markets Pipeline Access & Strategy at AbbVie (formerly Allergan) from 2019 to 2021; Vice President of Strategy & Corporate Initiatives at Allergan from 2015 to 2018; Principal at the Boston Consulting Group from 2011 to 2015; and, prior to that, Associate Partner at Monitor Group. Ms. Glass received her Master of Public Administration in International Affairs from Princeton University and Bachelor of Arts (magna cume laude) from Brown University.

Flemming Steen Jensen was named Executive Vice President, Product Supply and Quality at Ascendis Pharma after leading this function as Senior Vice President since 2015. Prior to Ascendis, Mr. Jensen served as Corporate Vice President for Global Pharma Consulting and Business Development and was a member of the management team at NNE Pharmaplan A/S, an engineering and consulting company (part of Novo Nordisk A/S), from October 2014 to July 2015. From 1999 to September 2014, Mr. Jensen served as Executive Vice President of Product Supply and was a member of the Board of Management of the pharmaceutical company ALK-Abelló A/S, Denmark. From 1986 to 1997, Mr. Jensen held several management positions relating to Development, Manufacturing and Engineering within Novo Nordisk A/S. Mr. Jensen is also a member of various Boards of Directors and Advisory Boards of privately held companies in the life sciences industry. Mr. Jensen holds a M.Sc. in Pharmacy from the University of Copenhagen.

Michael Wolff Jensen, L.L.M., was named Executive Vice President and Chief Legal Officer at Ascendis Pharma in January 2023, after serving as our Senior Vice President and Chief Legal Officer since 2013. Mr. Jensen served as Chairman of the Ascendis Pharma board of directors from January 2008 to May 2021, and as our Acting Chief Financial Officer from 2008 - 2013. Prior to Ascendis Pharma, Mr. Jensen served as Senior Legal Advisor and Head of Partnerships (France) for the renewable business division of Ørsted A/S, the Danish state-owned utility company from 2010 to 2013. Mr. Jensen served as Executive Vice President & Chief Financial Officer of LifeCycle Pharma A/S (now Veloxis Pharmaceuticals A/S), from 2003 to 2008. From 2000 to 2003, Mr. Jensen served as Senior Vice President & Chief Financial Officer of Genmab A/S. Mr. Jensen also currently serves as Chairman of the board of directors of VISEN Pharmaceuticals, and Vicore Pharma AB. Mr. Jensen received his L.L.M. degree from the University of Copenhagen.

Stina Singel, M.D., Ph.D., was named Executive Vice President, Head of Clinical Development, Oncology, at Ascendis Pharma in January 2023, after leading this function since May 2020. Prior to joining Ascendis Pharma, Dr. Singel served as Senior Vice President and Head of Clinical Development and Drug Safety at Nektar Therapeutics from 2019 to 2020 and as Senior Medical Director at Genentech from 2014- 2019. From 2017- 2019, Dr. Singel also served as an Adjunct Clinical Instructor at the Stanford University School of Medicine. From 2010 -2014 Dr. Singel was an Attending Physician and Clinical Translational Researcher focused on breast oncology at the University of Texas Southwestern Medical Center and from 2008- 2010 was a Medical Oncologist at Washington Hematology Oncology, a community practice in Yakima, Washington. Dr. Singel received her M.D. and Ph.D. degrees from the University of California, San Diego and The Salk Institute, where she also completed her internal medicine residency and medical oncology fellowship. She received her B.S. in Biology (magna cum laude) from Harvard University.

Scott Smith was named Executive Vice President and Chief Financial Officer at Ascendis Pharma in January 2023, after serving as our Senior Vice President and Chief Financial Officer since August 2016. Prior to joining Ascendis Pharma, Mr. Smith was at Wedbush Securities, where from 2012- 2016 he served as Director of the Healthcare Investment Banking Group at Wedbush Securities, leading the healthcare team, and oversaw a substantial increase in revenue and transaction volume, and from 2009 - 2012, he served as a Managing Director. Prior to Wedbush, Mr. Smith was a Director in the Global Healthcare Investment Banking Group at Merrill Lynch, where he began his career in 1995. He has also worked in sales, marketing and strategy roles for various companies, including start-ups and a Fortune Global 500 company. Mr. Smith received his M.B.A. from the Stanford University Graduate School of Business and his B.A. in Economics/Accounting – Physics (magna cum laude) from Claremont McKenna College.

Lotte Sønderbjerg was named Executive Vice President and Chief Administration Officer at Ascendis Pharma in January 2023, after serving as our Senior Vice President, Chief Administrative Officer since 2007. Mrs. Sønderbjerg is also Managing Director of Ascendis Pharma GmbH. Prior to joining Ascendis Pharma, Mrs. Sønderbjerg served as Senior Director of Human Resources and as Finance Director at LifeCycle Pharma A/S (now Veloxis Pharmaceuticals A/S) from 2003 to 2007. Prior to joining Veloxis, Mrs. Sønderbjerg served as Senior Director of Finance and Human Resources at Acadia Pharmaceuticals, Inc., from 1996 - 2003. Prior to her career in biotech, Mrs. Sønderbjerg was the Executive Secretary for the CEO and Board of Directors of Novo Nordisk A/S and PA to a leading audit partner in PricewaterhouseCoopers LLP (PwC) in Denmark. Mrs. Sønderbjerg received a Master of Arts in International Business Communications from University of Aarhus.

Kennett Sprogøe, Ph.D. was named Executive Vice President, Head of Research & Product Development at Ascendis Pharma in January 2023, and Head of Research & Product Development in July 2023, after holding positions of increasing responsibility since joining the company in 2007. These include Senior Vice President, Head of Innovation & Research 2019-2022, Senior Vice President of Product Innovation 2016-2018, and Vice President, Product Innovation 2014-2015. Prior to joining Ascendis Pharma, Dr. Sprogøe conducted research at the University of Copenhagen, where he applied novel hyphenated screening technologies to expedite discovery of drug leads from natural sources. Dr. Sprogøe holds a Ph.D. in Natural Products Chemistry from the University of Copenhagen and an M.Sc. in Pharmacy from the Danish University of Pharmaceutical Sciences.

Aimee D. Shu was named Executive Vice President, Endocrine & Rare Disease Medical Sciences and Chief Medical Officer at Ascendis Pharma in November 2024, where she leads Clinical Development, Clinical Operations, Biometrics, and Medical Affairs and oversees the clinical development strategy to support global marketing approvals and commercial launches across multiple geographies. Dr. Shu originally joined Ascendis as a Medical Director in 2017, serving as Senior Medical Director (2019-2020), Vice President, Endocrine Medical Sciences (2021-2023), and Senior Vice President, Acting Chief Medical Officer (2023-2024). Board-certified in Internal Medicine, Endocrinology, Diabetes, and Metabolism, Dr. Shu has been a practicing endocrinologist at Stanford University Health Care since 2012, where she also serves as Clinical Associate Professor of Medicine in the Division of Endocrinology. Prior to Stanford, Dr. Shu was an endocrinologist and Assistant Professor at the Baylor College of Medicine (2011) and the Columbia University Medical Center (2009-2010). After receiving her Bachelor of Arts from Princeton University and Doctor of Medicine from Harvard Medical School, Dr. Shu completed her residency and fellowship training at Brigham & Women’s Hospital (2003-2006) and Columbia Medical Center (2006-2009).

Jay Donovan Wu joined Ascendis Pharma in January 2025 as Executive Vice President and President, Ascendis US, where he is responsible for leading the US organization, spanning commercial, medical affairs, government affairs, and key business functions. Prior to Ascendis, Mr. Wu spent 13 years (2012-2025) at Genentech, where, most recently as Vice President and Head of Rare Diseases, he led the marketing, medical, field, access, advocacy, and operations teams to launch multiple products across neurology and hematology. Prior to this, he served in various leadership roles of increasing responsibility across Genentech’s Immunology and Oncology business units. Before joining Genentech, he worked as a consultant at Bain & Company, where he focused on healthcare and private equity. Mr. Wu received his MBA from the Stanford Graduate School of Business and his BSEc in Finance and BA in Neurobiology from the University of Pennsylvania.

Jethro Ekuta was named Chief Regulatory & Safety Officer at Ascendis Pharma in November 2024, where he heads Global Regulatory Affairs & Pharmacovigilance. Prior to joining Ascendis, Dr. Ekuta was Vice President, Head of Regulatory Science Delivery at Alexion, AstraZeneca Rare Disease (2019-2024), where he built Global Labeling, Established Products, and Advertising and Compliance Teams; served as US Regulatory Lead; and led various initiatives related to process improvement, talent development, and integrations and acquisitions. From 2018 to 2019, he served as Senior Vice President, Global Head of Regulatory, Safety and Standards at Horizon Therapeutics. Before Horizon, he held Regulatory and Pharmacovigilance roles of increasing responsibility at companies that included Johnson & Johnson, Genzyme-Sanofi, Bristol-Myers Squibb, Pfizer, and Procter & Gamble Pharmaceuticals. Prior to joining industry, Dr. Ekuta was a Staff Fellow in Clinical Pharmacology at the Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA). He completed his U.S. National Institutes of Health (NIH)-sponsored post-doctoral fellowship training in neuropharmacology and cardiovascular pharmacology at Meharry Medical College, and an FDA-sponsored post-doctoral fellowship in clinical pharmacology at Vanderbilt University Medical Center. Dr. Ekuta holds a Doctor of Veterinary Medicine (D.V.M.) degree from Ahmadu Bello University and a Ph.D. in Pharmacology & Toxicology from the University of Mississippi. He is certified in Regulatory Affairs (RAC) and is an inaugural Fellow of the Regulatory Affairs Professionals Society (FRAPS). Dr. Ekuta has served as President, RAPS Board of Directors (2023-2024) and currently serves as Chair of the Board..